[New antiretroviral drug classes in HIV therapy].
Lehmann
C
C
Klinik I für Innere Medizin, Klinikum der Universität zu Köln. clara.lehmann@uni-koeln.de
Meuer
K
K
Kümmerle
T
T
Fätkenheuer
G
G
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D000077592:Maraviroc; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000009:adverse effects / Q000627:therapeutic use; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D013386:Succinates / Q000009:adverse effects / Q000627:therapeutic use; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use; D014315:Triterpenes / Q000009:adverse effects / Q000627:therapeutic use; D019562:Viral Load; D053978:Pentacyclic Triterpenes
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D019428:HIV Integrase Inhibitors; D000077592:Maraviroc; D010879:Piperazines; D011743:Pyrimidines; D011760:Pyrrolidinones; D015363:Quinolones; D000068898:Raltegravir Potassium; D013386:Succinates; D014230:Triazoles; D014315:Triterpenes; C509700:elvitegravir; C479935:bevirimat; D053978:Pentacyclic Triterpenes; C486781:vicriviroc